Issue link: https://viewer.e-digitaledition.com/i/521055
at the forefront of Radiation Oncology, both clinically and academically." CyberKnife radiosurgery treatments are outpatient procedures that require no recovery period, surgical incision or blood loss. The most common side effects of radia- tion therapy for prostate cancer are urinary incontinence and impotence, according to the American Cancer Society. However, the Winthrop team finds CyberKnife patients experience these problems less frequently. "We treat a large number of prostate cancer patients and see far fewer side effects," Witten says. "Five-year data shows a reduction in the incidence of complications such as rectal bleeding and bladder issues that result from radiation toxicity, which is a consequence of normal structures in proximity to the prostate gland having been exposed to less radiation. This is attributable to the non-isocentric, non-coplanar design of the CyberKnife." The CyberKnife's unimpeachable preci- sion not only enhances radiation delivery but also provides a far more convenient treat- ment schedule. "Traditionally, we had recommended nine weeks of radiation or brachytherapy with radioactive prostate seeds, but we knew there had to be a better way," Dr. Haas says. "Prostate cancer treatment that used to require nine weeks of daily visits now requires only five, 20-minute CyberKnife treatments. Patients return to their lives in a week or less." Prostate cancer has a low alpha/beta ratio — a measurement clinicians use to determine a particular cancer's respon- siveness to radiation therapy — which makes it uniquely suitable for radio- therapy treatment, Dr. Haas notes. " C y b e r K n i f e delivers radiation in such a way that makes it a perfect modality for treat- ing prostate cancer," he says. "The biol- o g y o f p r o s t a t e c a n c e r i s s u c h that large doses of radiation over shorter periods of time are extremely effective." Although Winthrop providers work collaboratively, each member of the radia- tion oncology team brings a unique skillset. Witten's focus on radiation therapy research has led him to develop a meth- odology using computational intelligence for problem-solving techniques to address issues that may arise during radiotherapy treatment planning optimization. "The field is trending toward radiation treatments that use high-dose fractionation in the way CyberKnife does," Witten says. "Each study published seems to reflect that these treatments are effective for tumor control and produce acceptable rates of side effects, so it is wonderful that we are able to deliver high-dose fractionation on the CyberKnife with extreme accuracy every day." The team's expertise and commitment to advancing the application and access of CyberKnife technology brings a new level of treatment options throughout the tri-state area. "O ur physicist s bot h have a rea l sophistication and comprehension of how the machine architecture works, and that is truly invaluable and speaks to the incredible expertise of this team," Dr. Blacksburg says. "Winthrop-University Hospital has pioneered the adoption of CyberKnife technology to treat different malignan- cies, and it seemed like a natural extension of the phenomenal clinical success in Long Island to branch out and serve patients "CyberKnife delivers radiation to tumors with sub- millimeter accuracy, which is more accurate than any other conventional system on the market. With five times the accuracy, as well as real-time tracking of the tumor, CyberKnife makes it possible to expose less normal tissue to radiation, which results in a lower probability of side effects." — Matthew Witten, PhD, DABR, Chief Physicist of the Division of Radiation Oncology at Winthrop- University Hospital and Director of the Division of CyberKnife Radiosurgery at Winthrop's NYCyberKnife Center Clinical Advantage Researchers at Winthrop-University Hospital have found clear benefits associated with CyberKnife radiosurgery for prostate cancer treatment. Dr. Haas has personally treated more than 1,200 patients at the Long Island campus, where all data is meticulously tracked. "There is now data looking at patients treated with CyberKnife at Winthrop for seven years," Dr. Haas says. "Our outcome statistics are excellent — the majority of patients are cancer-free or have more than a 90 percent chance of being cured. In addition, we have a full time data manager who helps track all patients treated both in Mineola and Manhattan to help us remain Accuray's CyberKnife M6 Series, the latest CyberKnife model, which offers cutting-edge radiosurgery treatment with unprecedented accuracy, is available at Winthrop's NYCyberKnife Center. Matthew Witten, PhD, DABR, Chief Physicist of the Division of Radiation Oncology and Director of the Division of CyberKnife Radiosurgery at Winthrop- University Hospital COV ER FE AT UR E 8 | Lower Hudson/Bronx MD NEWS ■ M D N E W S . CO M

